The effectiveness of long-needle acupuncture at acupoints BL30 and BL35 for CP/CPPS: a randomized controlled pilot study

• Main Authors: Minjie Zhou (Author), Mingyue Yang (Author), Lei Chen (Author), Chao Yu (Author), Wei Zhang (Author), Jun Ji (Author), Chi Chen (Author), Xueyong Shen (Author), Jian Ying (Author)
• Format: Book
• Published: BMC, 2017-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/s12906-017-1768-2; 1472-6882
• Keywords: BL30; BL35; CP/CPPS; Acupuncture; Long needle; Other systems of medicine; RZ201-999
• Source: BMC Complementary and Alternative Medicine, Vol 17, Iss 1, Pp 1-6 (2017)

Abstract Background The chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the commonest chronic inflammatory diseases in adult men, for which acupuncture has been used to relieve related symptoms. The present study aimed to evaluate the therapeutic effect of the long-needle acupuncture on CP/CPPS. Methods A randomized traditional acupuncture-controlled single blind study was conducted on 77 patients who were randomized into long-needle acupuncture (LA) and traditional acupuncture (TA) groups. The patients received six sessions of acupuncture for 2 weeks and a follow-up was scheduled at week 24. The primary outcome was measured by the total National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) score at week 2. Four domains of the NIH-CPSI (urination, pain or discomfort, effects of symptoms, and quality of life) and the clinical efficacy score served as the secondary outcome. Results The total NIH-CPSI score at week 2 and week 24 was significantly improved in the LA group compared with the TA group. LA significantly improved urination, pain or discomfort, the effects of symptoms, and the quality of life at week 2 and week 24 and patients undergoing LA treatment had a higher clinical efficacy score. Conclusion Needling at the BL30 and BL35 using LA benefits patients with CP/CPPS. Trial registration The study was registered at the Chinese Clinical Trial Register ( ChiCTR-ICR-15006138 ).